FAQ

Bath Cancer Research DiSC assay for CLL endorsed by US government panel

If you are a patient, please read.......
The median isn’t the message.

Click here if you have problems opening Request Form

Click here for a colourful resumé of the work of Bath Cancer Research (2.4MB)

Cliquez ici pour nos lecteurs Français qui désirent plus d'information

New FAQ resource

Bath Cancer Research in the News! Click here for Leukaemia Research Hope in Bath. See also Kung Fu helps Cancer Research and Local Community cheers on Cancer Experts

Until further notice......June 2006. Bath Cancer Research has launched two far simpler, and therefore cheaper, drug sensitivity tests for CLL. These will allow physicians to test the main cytotoxic drugs of interest at diagnosis and also after the patients first regimen herbal male enhancement pills

TRAC-0 for untreated CLL patients - testing five drugs at just £95.00 (Euros 150.00). Drugs tested fludarabine, cyclophosphamide, mitoxantrone, chlorambucil, methylprednisolone.

TRAC-1 for CLL patients at first relapse - testing 10 drugs and costing £195.00 (Euros 300.00).

Click here for further details.

Apart from any prior agreement, other NHS tests will cost £395.00 + to test the sensitivity to 20+ cytotoxic drugs.

Research
Scientists at Bath Cancer Research undertake ex vivo drug sensitivity studies using the TRAC assay (Tumour Response to Anti-neoplastic Compounds, a development of the DiSC assay [Ref. 10 of Selected Publications]). With this we assess the cytotoxic drug sensitivity of fresh human cells from patients with leukaemia and lymphoma. Our greatest expertise is with chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML or ANLL), non-Hodgkin's lymphoma (NHL) and similar diseases.

Service
Bath Cancer Research provides consultant haematologists/ oncologists an international service for the diseases above. Cells from their patients are tested for ex vivo drug response to a panel of cytotoxic drugs (up to 25 drugs). A report is sent to the physician to aid choice of optimum therapy. This information helps maximise the likelihood of response (and therefore survival) and reduces the risk of causing patient toxicity with no clinical benefit. Some assays are chargeable.

For those interested in assays for solid tumours or tests in the USA, please see links at the bottom of this page.

New Drug Screening
herbal erectile dysfunction pills. Bath Cancer Research tests new cytotoxic agents in "Ex vivo Phase II trials" (Ref 14 of Selected Publications]. A new drug is tested against tumour cells from a variety of diseases as well as normal cells. This can elucidate targets for further clinical Phase II or Phase III trials, provide information about cross-resistance with known cytotoxic drugs and produce an ex vivo therapeutic index.